Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Lymphatic dissemination from the primary tumor is a major mechanism by which breast cancer cells access the systemic circulation, resulting in distant metastasis and mortality. Numerous studies link activation of hypoxia-inducible factor 1 (HIF-1) with tumor angiogenesis, metastasis, and patient mortality. However, the role of HIF-1 in lymphatic dissemination is poorly understood. In this study, we show that HIF-1 promotes lymphatic metastasis of breast cancer by direct transactivation of the gene encoding platelet-derived growth factor B (PDGF-B), which has proliferative and chemotactic effects on lymphatic endothelial cells. Lymphangiogenesis and lymphatic metastasis in mice bearing human breast cancer orthografts were blocked by administration of the HIF-1 inhibitor digoxin or the tyrosine kinase inhibitor imatinib. Immunohistochemical analysis of human breast cancer biopsies demonstrated colocalization of HIF-1α and PDGF-B, which were correlated with lymphatic vessel area and histological grade. Taken together, these data provide experimental support for breast cancer clinical trials targeting HIF-1 and PDGF-B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remarkably, immunohistochemistry revealed that there was no association between HIF-1α and PDGF-B levels in biopsies from grade 1 breast cancers but an association was observed in grade 2 and grade 3 cancers, suggesting that HIF-1α was necessary but not sufficient for PDGFB gene expression during breast cancer progression [31].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“HIF-1α inhibition has shown success as a therapeutic strategy in mouse models of metastatic breast cancer6, 7.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoxia induced the binding of HIF-1 to a hypoxia response element located within intron 3 of the PDGFB gene.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“HIF-dependent expression of platelet-derived growth factor B (PDGF-B) was required for, and PDGF-B knockdown eliminated, the effects of hypoxia on lymphatic EC migration and proliferation in vitro; PDGF-B knockdown also decreased lymphatic vessel density and lymph node metastasis in vivo [31].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [31]
In the citing paper
“Conditioned medium, which was collected from BCCs cultured under hypoxic conditions, increased the migration and proliferation of lymphatic ECs, whereas the effects of hypoxia were lost when HIF-1α and HIF-2α shRNA was expressed [31].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [31]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326 · cited 3×
“Treatment of tumorbearing mice with digoxin, a drug that inhibits HIF activity, also impaired primary tumor growth and lung metastasis (10, 11).”
BackgroundSelf-citationRetractedELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 1×
“Exposure of MDA-MB-231 cells to the prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG), which blocks HIF-1α and HIF-2α degradation (23), stimulated increased PDGF-B expression as determined by flow A”
BackgroundBloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Self-citationLymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,441
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
Hirakawa, S., Kodama, S., Kunstfeld, R., Kajiya, K., Brown, L. F., & Detmar, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041896 · Cited by 719
Kelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S., Rowan, A., Yan, Z., Campochiaro, P. A., & Semenza, G. L. (2003) · Circulation Research · doi:10.1161/01.res.0000102937.50486.1b · Cited by 611
Self-citationNagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
Cao, R., Björndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F., Tritsaris, K., Dissing, S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.034 · Cited by 527
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500 · cited 2×
“Clinical studies have found that increasedHIF-1α levels in primary breast tumors are significantly associated with peritumoral LV density (12) and patient mortality (13).”
BackgroundSelf-citationTumor hypoxia and malignant progression
Vaupel, P., Mayer, A., & Höckel, M. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)81023-1 · Cited by 496 · cited 1×
“5% O2)] is associated with a significantly increased risk of metastasis and patient mortality (6).”
BackgroundCancer burden in the aged: An epidemiologic and demographic overview
Yancik, R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1273::aid-cncr13>3.0.co;2-4 · Cited by 473
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437 · cited 1×
“We previously demonstrated that stable transfection of MDA-MB-231 human BCCs with lentiviral vectors encoding shRNA to knock down the expression of HIF-1α (1αKD), HIF-2α (2αKD), or double knock down of both HIF-1α and HIF-2α (DKD) resulted in decreased primary tumor growth and lung metastasis compared with cells trans…”
BackgroundSelf-citationLymph node micrometastases from breast carcinoma: Reviewing the dilemma
Dowlatshahi, K., Fan, M., Snider, H. C., & Habib, F. A. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1188::aid-cncr2>3.0.co;2-h · Cited by 430
(2002) · PubMed · Cited by 385
Focus on lymphangiogenesis in tumor metastasis
Achen, M. G., McColl, B. K., & Stacker, S. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.017 · Cited by 351
Liao, D., Corle, C., Seagroves, T. N., & Johnson, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2701 · Cited by 339 · cited 1×
“HIF-1α is required for vascular metastasis from breast to lung in autochthonous (8) and orthotopic transplantation (9–11) mouse models.”
BackgroundOhta, Y., Shridhar, V, Bright, R. K., Kalemkerian, G. P., Du, W., Carbone, M., Watanabe, Y., & Pass, H. I. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690650 · Cited by 335
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
Cao, Y. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1693 · Cited by 307
Gleadle, J. M., Ebert, B. L., Firth, J. D., & Ratcliffe, P. J. (1995) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1995.268.6.c1362 · Cited by 270
Pharmacology of imatinib (STI571)
Buchdunger, E., O'Reilley, T., & Wood, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80600-1 · Cited by 269
Lymphangiogenesis and lymphatic metastasis in breast cancer
Ran, S., Volk, L., Hall, K., & Flister, M. J. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2009.11.003 · Cited by 250
Wong, C. C.-L., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M. E., & Semenza, G. L. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0855-y · Cited by 225
Self-citationBos, R., Van Diest, P. J., De Jong, J. S., Van Der Groep, P., Van Der Valk, P., & Van Der Wall, E. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02045.x · Cited by 180
Vascular Endothelial Growth Factor-A Promotes Peritumoral Lymphangiogenesis and Lymphatic Metastasis
Björndahl, M. A., Cao, R., Burton, J. B., Brakenhielm, E., Religa, P., Galter, D., Wu, L., & Cao, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2345 · Cited by 178
Franco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A. M., Brown, A. S., Hicklin, D. J., Foster, F. S., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3295 · Cited by 162
Su, L., Sampaio, A. V., Jones, K. B., Pacheco, M., Goytain, A., Lin, S., Poulin, N., Yi, L., Rossi, F. M. V., Kast, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.010 · Cited by 159
Kurokawa, T., Miyamoto, M., Kato, K., Cho, Y., Kawarada, Y., Hida, Y., Shinohara, T., Itoh, T., Okushiba, S., Kondo, S., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601186 · Cited by 142
Liang, X., Yang, D., Hu, J. R., Hao, X., Gao, J., & Mao, Z. (2008) · PubMed · Cited by 123
Amat, S., Penault-Llorca, F. M., Curé, H., Bouëdec, G. L., Achard, J. L., Praagh, I. V., Feillel, V., Mouret‐Reynier, M., Dauplat, J., & Chollet, P. J. M. (2002) · International Journal of Oncology · doi:10.3892/ijo.20.4.791 · Cited by 118
Yoshida, D., Kim, K., Noha, M., & Teramoto, A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-3279-0 · Cited by 107
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., Horvat, R., Jakesz, R., & Birner, P. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9190-3 · Cited by 106 · cited 2×
“Previous descriptive studies reported correlations between HIF-1α expression and VEGF-C, FGF-2, and PDGF-B in breast cancer (12, 20), gastric carcinoma (21), squamous cell carcinoma (14, 17), and mesothelioma (31).”
BackgroundZhang, S. X. L., Gozal, D., Sachleben, L. R., Rane, M. J., Klein, J. B., & Gozal, E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1111fje · Cited by 102
Kodama, M., Kitadai, Y., Sumida, T., Ohnishi, M., Ohara, E., Tanaka, M., Shinagawa, K., Tanaka, S., Yasui, W., & Chayama, K. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01639.x · Cited by 83
Mohammed, R. A., Ellis, I. O., Elsheikh, S. E., Paish, E. C., & Martin, S. G. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9936-1 · Cited by 71
Koyama, Y., Kaneko, K., Akazawa, K., Kanbayashi, C., Kanda, T., & Hatakeyama, K. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.041 · Cited by 43
Hypoxia Increases Breast Cancer Cell-Induced Lymphatic Endothelial Cell Migration
Mikhaylova, M., Mori, N., Wildes, F. B., Walczak, P., Gimi, B., & Bhujwalla, Z. M. (2008) · Neoplasia · doi:10.1593/neo.07854 · Cited by 33
Ullerås, E., Wilcock, A. C., Miller, S. J., & Franklin, G. C. (2001) · Growth Factors · doi:10.3109/08977190109001089 · Cited by 27
Research works printed but not linked: 7
- Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. 2010;17:229–251. doi: 10.1016/j.pathophys.2009.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- Semenza GL. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207–214. doi: 10.1016/j.tips.2012.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- Zhang H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31:1757–1770. doi: 10.1038/onc.2011.365. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted] · DOI · Paper page
- Wong CC, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012;90:803–815. doi: 10.1007/s00109-011-0855-y. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- Bos R, et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573–1581. doi: 10.1002/cncr.11246. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- Pal SK, Childs BH, Pegram M. Triple negative breast cancer: Unmet medical needs. Breast Cancer Res Treat. 2011;125:627–636. doi: 10.1007/s10549-010-1293-1. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):15991–15992.
Cited by
Hypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520
Self-citationHIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Self-citationOxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159
Self-citationThe hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Self-citation
Metadata
- Authors
- Schito, L., Rey, S., Tafani, M., Zhang, H., Wong, C. C.-L., Russo, A., Russo, M. A., & Semenza, G. L.
- Affiliations
- Sapienza University of Rome (IT)
- Johns Hopkins University (US)
- Istituti Fisioterapici Ospitalieri (IT)
- IRCCS San Raffaele Roma (IT)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-09-10
- Volume
- 109
- Issue
- 40
- Pages
- E2707-16
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3479586
- OpenAlex
- W2016626122
- Cited by
- 224
- References
- 42
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 13 · 2023: 11 · 2022: 26 · 2021: 18 · 2020: 23 · 2019: 13 · 2018: 13 · 2017: 12 · 2016: 16 · 2015: 15 · 2014: 20 · 2013: 22 · 2012: 2
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, HIF-1α, platelet-derived growth factor B, PDGF-B, lymph node metastasis, breast cancer, lymphangiogenesis, tumor hypoxia, digoxin, imatinib, tyrosine kinase inhibition, lymphatic endothelial cells
- MeSH terms
- Imatinib Mesylate, Benzamides, Breast Neoplasms, Digoxin, Female, Humans, Immunohistochemistry, Luciferases, Lymphatic Metastasis, Piperazines, Pyrimidines, Immunoblotting, Transcriptional Activation, Cell Hypoxia, Proto-Oncogene Proteins c-sis, RNA, Small Interfering, Lymphangiogenesis, Cell Line, Tumor, Chromatin Immunoprecipitation, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.